AbbVie Inc. settled claims by New York and two of the state’s counties that the company fueled an epidemic of opioid addiction in the state, on the day jurors were expected to hear closing arguments at the end of a five-month trial.
Theranos founder Elizabeth Holmes denied making misleading statements about the blood-testing startup during cross-examination on December 7, as her testimony in defense against fraud charges neared its end.
A trial pitting Washington state against McKesson Corp. and two other drug distributors accused of fueling the U.S. opioid epidemic was slated to kick off on November 15, after the state’s attorney general declined to join a $26 billion nationwide settlement.
One week after a retired Pfizer scientist testified that Theranos inappropriately used the pharma giant’s company logo in marketing materials sent to Walgreens, suggesting its participation in research, a second researcher from a different company made a similar claim.
After a year-long delay due to Covid-19, Theranos founder and CEO Elizabeth Holmes headed to court on Sept. 8 to face multiple criminal fraud charges that could land the former billionaire in prison for more than a decade.
The three largest U.S. drug distributors, facing their first trial over claims that they fueled the opioid crisis, said responsibility for ballooning painkiller sales lies with doctors, drugmakers and regulators.
A highly anticipated trial pitting New York state against McKesson Corp., Johnson & Johnson, CVS Health Corp. and others for allegedly fueling the opioid epidemic was postponed due to the coronavirus outbreak, according to the court.
Teva Pharmaceutical agreed to pay an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that the world’s largest generic manufacturer and other drugmakers helped fuel the U.S. opioid epidemic.
A California jury awarded $29 million to a woman who said abestos in Johnson & Johnson’s talcum-powder-based products caused her cancer.
Amgen Inc. said a U.S. jury confirmed the validity of patents on the biotech company’s cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc. and Sanofi SA.